BiolineRX To Raise $21M On Secondary Nasdaq Offering

March 5, 2014 | Israeli drug development company BiolineRX is planning a secondary offering on Nasdaq, in an attempt to raise $21 million. The company will use the proceeds for a Phase II clinical trial of its leukemia treatment and a Phase I clinical trial of its celiac disease treatment.